Thursday 15 October 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGEN Healthcare Biotechnology
Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.
2.08
0.08
+4.00%
Follow CGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 4.14 | 5.76 | 5.63 |
P/S ratio |
19.92 | 1.96 | 2.77 | 2.74 | |
P/FCF ratio |
3.08 | 1.41 | 1.98 | 5.06 | |
P/Operating CF |
(7.41) | 4.52 | 6.37 | (9.23) | |
P/B ratio |
1.34 | 1.39 | 1.96 | 2.28 | |
Price to Tangible BV |
1.34 | 1.39 | 1.96 | 2.28 | |
EV/Sales |
7.45 | (0.04) | 0.91 | 1.04 | |
EV/EBITDA |
0.00 | 0.00 | 2.16 | 2.55 | |
EV/Operating CF |
1.14 | (0.03) | 0.65 | 1.90 | |
EV/FCF |
1.15 | (0.03) | 0.65 | 1.93 | |
Quick Ratio |
4.38 | 6.56 | 6.23 | 5.72 | |
Current Ratio |
4.38 | 6.56 | 6.23 | 5.72 | |
Net Debt/EBITDA |
10.91 | (2.60) | 14.97 | 14.18 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.54 | 0.56 | 0.50 | |
Operating CF/Net income |
0.00 | 0.56 | 0.00 | 3.13 | |
Capex/Depreciation |
— | 30.50 | — | (0.26) | |
Research and Development Expense of Revenue |
306.72% | 8.23% | 318.80% | 242.43% | |
Selling, General and Administrative Expense of Revenue |
123.43% | 3.28% | 111.76% | 93.66% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.25 | 0.66 | 0.43 | 0.39 | |
Graham Number |
0.00 | 3.03 | 0.00 | 2.83 | |
Earnings Yield |
(20.41%) | 24.18% | 17.37% | 17.76% | |
Free Cash Flow Yield |
32.42% | 71.14% | 50.49% | 19.77% | |
Revenue per Share |
0.02 | 0.72 | 0.02 | 0.03 | |
Operating CF per Share |
0.00 | 0.34 | 0.00 | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.34 | 0.00 | (0.23) | |
Cash per Share |
0.92 | 1.56 | 1.43 | 1.32 | |
Shareholders Equity per Share |
0.47 | 1.10 | 1.01 | 0.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.47 | 1.10 | 1.01 | 0.94 | |
Free Cash Flow |
— | 31.33 | — | (21.98) | |
Working Capital |
68.64 | 125.45 | 115.25 | 106.78 | |
Capital Expenditures |
— | (0.30) | — | (0.04) | |
Net Current Asset Value |
34.90 | 94.18 | 86.78 | 79.78 | |
EV/EBIT |
0.00 | 0.00 | 2.16 | 2.55 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 4.56 | 6.56 | 6.69 | |
| Other line items | |||||
Average Receivables |
2.48 | 2.56 | 2.74 | 3.25 | |
Average Payables |
— | 2.93 | 2.45 | 2.00 | |
Average Assets |
110.68 | 135.78 | 130.65 | 147.47 | |
Average Common Equity |
— | 84.15 | — | 73.54 |
Columns are period end dates